Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Account Payables (2016 - 2025)

Fennec Pharmaceuticals' Change in Account Payables history spans 12 years, with the latest figure at -$1.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 96.65% year-over-year to -$1.2 million, compared with a TTM value of $1.4 million through Dec 2025, up 359.59%, and an annual FY2025 reading of $1.4 million, up 359.59% over the prior year.
  • Change in Account Payables for Q4 2025 was -$1.2 million at Fennec Pharmaceuticals, down from -$75000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $2.0 million in Q1 2025, with the low at -$1.8 million in Q2 2021.
  • Average Change in Account Payables over 5 years is $125352.9, with a median of $58000.0 recorded in 2023.
  • Year-over-year, Change in Account Payables soared 1387.3% in 2021 and then tumbled 1405.17% in 2024.
  • Tracing FENC's Change in Account Payables over 5 years: stood at $477000.0 in 2021, then tumbled by 130.19% to -$144000.0 in 2022, then surged by 681.25% to $837000.0 in 2023, then plummeted by 174.79% to -$626000.0 in 2024, then tumbled by 96.65% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Change in Account Payables are -$1.2 million (Q4 2025), -$75000.0 (Q3 2025), and $661000.0 (Q2 2025).